Skip to main content
Top

19-04-2024 | Biomarkers | Letter to the Editor

Letter to the Editor in regards to the article “Prognosticating acute traumatic spinal cord injury using Neurofilament (NF), Neuron Specific Enolase (NSE), Matrix Metalloproteinases (MMPs), and S-100B as biomarkers”

Authors: Adarsh Tekumalla, Vikash Raj

Published in: Irish Journal of Medical Science (1971 -)

Login to get access

Excerpt

Dear Editor, …
Literature
3.
go back to reference Stukas S, Cooper J, Gill J et al (2023) Association of CSF and serum neurofilament light and glial fibrillary acidic protein, injury severity, and outcome in spinal cord injury. Neurology 100(12) Stukas S, Cooper J, Gill J et al (2023) Association of CSF and serum neurofilament light and glial fibrillary acidic protein, injury severity, and outcome in spinal cord injury. Neurology 100(12)
Metadata
Title
Letter to the Editor in regards to the article “Prognosticating acute traumatic spinal cord injury using Neurofilament (NF), Neuron Specific Enolase (NSE), Matrix Metalloproteinases (MMPs), and S-100B as biomarkers”
Authors
Adarsh Tekumalla
Vikash Raj
Publication date
19-04-2024
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -)
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-024-03691-9
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine